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a b s t r a c t
Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that has shown significant anticancer activ-
ity. Sulindac sulfide amide (1) possessing greatly reduced COX-related inhibition relative to sulindac dis-
played in vivo antitumor activity that was comparable to sulindac in a human colon tumor xenograft
model. Inspired by these observations, a panel of diverse sulindac amide derivatives have been synthe-
sized and their activity probed against three cancer cell lines (prostate, colon and breast). A neutral ana-
log, compound 79 was identified with comparable potency relative to lead 1 and activity against a panel
of lymphoblastic leukemia cell lines. Several new series also show good activity relative to the parent (1),
including five analogs that also possess nanomolar inhibitory potencies against acute lymphoblastic leu-
kemia cells. Several new analogs identified may serve as anticancer lead candidates for further
development.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a chemically
diverse family of drugs commonly used clinically to treat a variety
of inflammatory conditions including pain associatedwith arthritis.
A number of these drugs possess antipyretic activity in addition to
having analgesic and anti-inflammatory action, and thus have util-
ity in the treatment of pain and fever. These are widely known to be
cyclooxygenase (COX) inhibitors. The COX enzymes participate in
the metabolism of prostaglandins. For example, COX-1 enzymes
produce prostaglandins that are important for the stomach lining
and kidney function. COX-2 enzymes are crucial to anti-inflamma-
tory reactions in the body.1 Many currently marketed NSAIDs have
both COX-1 and COX-2 inhibitory effects. Although the class is
highly used both clinically and over the counter, chronic COX inhi-
bition is associated with gastrointestinal, renal, and cardiovascular
side effects.2–6 Epidemiological, preclinical, and clinical studies sug-
gest that NSAIDs and COX-2 inhibitors display striking cancer
chemopreventive efficacy by reducing cancer incidence in the gen-
eral population.1,7,8 Although the mechanism responsible for the
anticancer activity of NSAIDs is still unknown, it is commonly
attributed to COX-2mediation.9–11 Studies have shown that several
human tumors contain increased levels of COX-2 as compared to
normal tissues. It has been determined that excess expression of
COX-2 in cancer cells correlates to increased tumorigenic potential.
Experiments have demonstrated that COX-2 specificNSAIDs restore
apoptotic responses, or programmed cell death, in tumor cells. By
selective enzyme inhibition and restoration of normal apoptotic
responses, research data support the hypothesis that the anti-can-
cer mechanism is COX-2 dependent. Several COX-2 independent
mechanisms have also been postulated for the antineoplastic prop-
erties of NSAIDs including activation of apoptosis, inhibition of
angiogenesis, or direct inhibition of cancer cell growth by blocking
signal transduction pathways responsible for cell proliferation.12–15
A number of molecular targets have been implicated in the
cyclooxygenase independent pathways of anti-cancer effects of
NSAIDs, as reviewed recently,16,17 and it was our intention to
develop potential probes for these activities through ready
variations in the scaffold.
Sulindac, or Clinoril, is a substituted indene-3-acetic acid, and is
a clinically used NSAID with established chemopreventive activ-
ity.13 Sulindac contains a chiral center (the sulfoxide), although
the commercial drug is sold as a racemic mixture. In the body,
the drug exists primarily in three active forms (see Fig. 1) due to
oxidation-reduction cycling. This cycling scrambles chirality at
http://dx.doi.org/10.1016/j.bmcl.2017.09.022
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the SO bond and oxidation to the sulfone is irreversible.13 The sul-
fide metabolite generated through bioreduction in vivo is a potent,
non-selective COX enzyme inhibitor and shows compelling anti-
cancer activity as compared with other NSAIDS.
Based on our and others’ data, it is clear that the NSAIDs have
multifarious actions ranging from anti-inflammatory and anti-pro-
liferative effects to selective anticancer cytotoxic activity.1,18 The
fact that NSAIDs are relatively safe and orally effective suggests
that there is an opportunity through simple, specific alterations
of the diverse scaffolds to modify the basic structure to probe these
various activities, and, at the same time, produce derivations that
are more likely to yield good biological probes, animal activity,
and drug leads. As an example, the preparation of neutral carbox-
amides is known to bias the NSAID scaffold towards selective COX-
2 activity. As well, and supported by our preliminary results that
replacement of the carboxylate functionality in sulindac in the
form of sulindac sulfide amide (SSA) (1) can virtually abolish
COX-related activity and toxicity while potentiating anticancer
activity in vitro and yielding in vivo xenograft activity.18 These
results are promising in that sulindac derivatives lacking the car-
boxylate functionality may show attenuated toxicity (gastric, renal,
and cardiovascular) associated with COX inhibition. The presented
chemical modifications have begun to explore, and possibly
improve on, other NSAID activity space relating to selective cancer
prevention and therapy.
Herein, we describe the synthesis and anti-cancer activity of a
series of sulindac analogs. Compound 1 (SSA) was considered the
lead compound, and for this study two modification sites were
chosen, the methylthiophenyl ring, and the acetamide linker
(Fig. 2). Various aryl groups were introduced in the indene core
ring and a series of amides and sulfonamides were synthesized.
All compounds were screened against three cancer cell lines (pros-
tate, colon and breast) and selected compounds against a panel of
additional cancer cell lines (five leukemia cancer cell lines and
choroid plexus carcinoma cell line).
Chemistry
Compounds 1–86 were synthesized by the coupling of different
sulindac derivatives with various amines using either HBTU19 or
HATU20 as the coupling agent (Scheme 1). Sulindac derivatives, if
not commercially available, were synthesized from 2-(5-fluoro-2-
methyl-1H-inden-3-yl)acetic acid and the corresponding aryl alde-
hydes in the presence of NaOMe.21
N,N0-Dimethylaminoethyl derivatives of various sulindac ana-
logs (10, 22, 31) were treated with Boc-L-valine under the same
coupling reaction conditions followed by hydrolysis for the
removal of Boc protecting group to produce 87–89 in good yields.
Sulfonamides 90–103 were also synthesized from amides, 10 and
22 by reacting with suitable sulfonyl chlorides in pyridine and N-
methylimidazole (Scheme 2).
Screening results
Using quantitative high-throughput screening all reported com-
pounds were evaluated against PC3 prostate, HT29 colorectal car-
cinoma and MDA-MB-231 breast cancer cell lines. Description of
the assays and screening method is provided in Appendix A, sup-
plementary materials. SSA (1) was identified earlier as a lead com-
pound for our structure-activity relationship (SAR) study with
modification at the methylthiophenyl ring, and the acetamide lin-
ker. Amides shown in Scheme 1 were categorized as acyclic basic
amides (Table 1), cyclic basic amides (Table 2), aromatic basic
amides (Table 3) and neutral amides (Table 4). Screening data for
the acyclic basic amides with modifications at the 4-methylth-
iobenzylidene ring at the C-1 position are shown in Table 1. First,
the effect of various acyclic basic amide linkers at the C-3 position
Fig. 1. In vivo metabolism (oxidation/reduction cycling) of the ASOCH3 center.
Fig. 2. Outline of structural modifications on the lead compound 1.
Scheme 1. Synthetic pathway to analogs 1–86. Reagents: (a) HBTU or HATU, TEA or
DIEA, MeCN.
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Scheme 2. 87–103. Reagents and conditions: (a) HBTU, TEA, Boc-L-valine, MeCN (b) H+ (c) RSO2Cl, NMI, Pyridine, 0 C.
Table 1
Screening data for control 1 and basic acyclic amides 2–37.
Ar Cmpd R1 and R2 CC50 (mM)
HT29 PC3 MDA-MB-231
1 R1 = H, R2 = ACH2CH2N(CH3)2 0.65 ± 0.03 3.12 ± 0.15 2.67 ± 0.08
2 R1 = H, R2 = ACH2CH2CH2N(CH3)2 2.46 ± 0.14 6.99 ± 0.19 5.18 ± 0.46
3 R1 = H, R2 = ACH2CH2N(CH2CH3)2 1.54 ± 0.05 5.45 ± 0.35 4.20 ± 0.17
4 R1 = H, R2 = ACH2CH2CH2N(CH2CH3)2 1.53 ± 3.33 4.33 ± 0.22 3.19 ± 0.08
5 R1 = CH3, R2 = ACH2CH2N(CH3)2 1.83 ± 0.04 5.63 ± 0.26 3.98 ± 0.45
6 R1 = CH3, R2 = ACH2CH2CH2N(CH3)2 2.18 ± 0.03 6.98 ± 0.27 5.41 ± 0.42
7 R1 = CH2CH3, R2 = ACH2CH2N(CH2CH3)2 1.83 ± 0.04 6.21 ± 0.44 5.22 ± 0.20
8 R1 = CH3, R2 = ACH2CH2N(CH2CH3)2 1.49 ± 0.02 5.65 ± 0.26 3.77 ± 0.35
9 R1 = CH2CH3, R2 = ACH2CH2N(CH3)2 1.36 ± 0.05 5.07 ± 0.31 3.96 ± 1.46
10 R1 = CH3, R2 = ACH2CH2N(CH3)H 2.80 ± 0.07 6.75 ± 0.24 5.84 ± 0.35
11 R1 = CH3, R2 = ACH2CH2CH2N(CH3)H 2.90 ± 0.05 7.65 ± 0.29 7.66 ± 0.49
12 R1 = CH2CH3, R2 = ACH2CH2N(CH2CH3)H 2.54 ± 0.10 6.56 ± 0.43 6.65 ± 0.22
13 R1 = CH2CH3, R2 = ACH2CH2CH2N(CH2CH3)H 1.38 ± 0.05 3.92 ± 0.29 3.03 ± 0.19
14 R1 = CH(CH3)2, R2 = ACH2CH2CH2N(CH(CH3)2)H 2.30 ± 0.07 4.90 ± 0.23 3.92 ± 0.39
15 R1 = H, R2 = ACH2CH2CH2N(CH3)2 33.27 ± 2.92 >50.00 >50.00
16 R1 = H, R2 = ACH2CH2N(CH2CH3)2 19.78 ± 0.77 >50.00 >50.00
17 R1 = H, R2 = ACH2CH2CH2N(CH2CH3)2 27.12 ± 2.0 >50.00 >50.00
18 R1 = CH3, R2 = ACH2CH2CH2N(CH3)2 38.92 ± 7.98 >50.00 >50.00
19 R1 = CH2CH3, R2 = ACH2CH2N(CH2CH3)2 18.40 ± 0.78 >50.00 >50.00
20 R1 = CH3, R2 = ACH2CH2N(CH2CH3)2 23.97 ± 1.51 >50.00 >50.00
21 R1 = CH2CH3, R2 = ACH2CH2N(CH3)2 18.15 ± 0.94 >50.00 >50.00
22 R1 = CH3, R2 = ACH2CH2N(CH3)H 34.53 ± 2.45 >50.00 >50.00
23 R1 = CH3, R2 = ACH2CH2CH2N(CH3)H >50.00 >50.00 >50.00
24 R1 = CH2CH3, R2 = ACH2CH2N(CH2CH3)H 18.18 ± 1.40 >50.00 >50.00
25 R1 = CH2CH3, R2 = ACH2CH2CH2N(CH2CH3)H 17.48 ± 1.14 >50.00 >50.00
26 R1 = CH(CH3)2, R2 = ACH2CH2CH2N(CH(CH3)2)H 16.28 ± 0.97 48.28 ± 8.05 >50.00
27 R1 = H, R2 = ACH2CH2N(CH3)2 6.22 ± 0.44 18.27 ± 1.34 15.05 ± 0.88
28 R1 = H, R2 = ACH2CH2CH2N(CH3)2 6.08 ± 0.30 13.03 ± 0.74 10.79 ± 0.45
29 R1 = H, R2 = ACH2CH2N(CH2CH3)2 5.42 ± 0.38 13.88 ± 0.78 12.26 ± 0.34
30 R1 = CH3, R2 = ACH2CH2N(CH3)2 4.68 ± 0.23 11.44 ± 0.52 10.78 ± 0.65
31 R1 = CH3, R2 = ACH2CH2N(CH3)H 8.05 ± 0.31 23.06 ± 1.31 16.96 ± 1.04
32 R1 = H, R2 = ACH2CH2N(CH3)2 1.57 ± 0.07 4.88 ± 0.53 3.63 ± 0.27
33 R1 = H, R2 = ACH2CH2CH2N(CH3)2 1.05 ± 0.05 3.25 ± 0.13 1.93 ± 0.13
34 R1 = H, R2 = ACH2CH2N(CH2CH3)2 1.12 ± 0.05 4.48 ± 0.32 3.54 ± 0.24
35 R1 = CH3, R2 = ACH2CH2N(CH3)2 2.02 ± 0.06 5.88 ± 0.32 3.80 ± 0.51
36 R1 = H, R2 = ACH2CH2N(CH3)2 6.89 ± 0.58 28.90 ± 2.05 18.06 ± 1.07
37 R1 = H, R2 = ACH2CH2N(CH3)2 12.67 ± 0.73 >50.00 37.46 ± 3.45
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was explored (2–14) while retaining the 4-thiomethylbenzylidene
group at the C-1 position.
Among these 13 compounds, none was found to be more active
compared to the lead agent 1 although many showed relatively
comparable cell growth inhibition. Simple modifications of the N,
N-dimethylaminoethylamino group of 1 reduced the activity by
2–5-fold. Compound 2, with a N,N-dimethylpropyl substitution at
the acetamide linker, reduced the activity by 4-fold compared to
Table 2
Screening data for basic cyclic amides 38–66.
Ar Cmpd R1 and R2 CC50 (mM)
HT29 PC3 MDA-MB-231
38 R1 = H, R2 = 1.81 ± 0.06 5.27 ± 0.32 3.78 ± 0.26
39 R1 = H, R2 = 1.65 ± 0.14 5.36 ± 0.18 5.42 ± 0.24
40 R1 = H, R2 =
2.98 ± 18.68 6.66 ± 0.43 7.66 ± 0.52
41 R1 = H, R2 = 1.41 ± 0.04 4.33 ± 0.23 3.75 ± 0.23
42 R1 = H, R2 = 1.16 ± 0.08 4.64 ± 0.23 3.72 ± 0.23
43 R1, R2 = 1.55 ± 0.06 5.10 ± 0.36 4.16 ± 0.29
44 R1, R2 = A(ACH2CH2A)2NCH2CH2CH2N
(CH3)2
1.69 ± 0.08 4.28 ± 0.16 3.77 ± 1.18
45 R1, R2 = A(ACH2CH2A)2NCH2CH2N
(CH3)2
2.17 ± 0.06 6.23 ± 0.37 4.05 ± 0.23
46 R1, R2 = A(ACH2CH2A)2N(pyridin-4-yl) 1.13 ± 0.07 2.76 ± 0.19 3.08 ± 0.07
47 R1, R2 =A(ACH2CH2A)2CH(pipyridin-1-yl) 1.06 ± 0.05 4.06 ± 0.27 2.61 ± 0.09
48
R1 = H, R2 =
1.64 ± 0.07 4.45 ± 0.16 4.10 ± 0.19
49
R1, R2 =
4.29 ± 0.19 13.42 ± 0.49 11.50 ± 0.53
50
R1, R2 =
2.94 ± 0.16 7.35 ± 0.32 7.21 ± 0.22
51
R1, R2 =
2.47 ± 0.67 6.50 ± 0.84 3.69 ± 0.17
52 R1, R2 = A(ACH2CH2A)2NCH2CH2CH2N
(CH3)2
23.75 ± 1.48 >50.00 46.18 ± 2.63
53 R1, R2 = A(ACH2CH2A)2N(Pyridin-4-yl) 9.20 ± 0.39 21.93 ± 2.16 22.74 ± 2.29
54 R1, R2 =A(ACH2CH2A)2CH(pipyridin-1-yl) >50.00 >50.00 >50.00
55 R1 = H, R2 = 19.03 ± 1.26 >50.00 >50.00
56 R1, R2 = 20.16 ± 1.06 >50.00 >50.00
57
R1 = H, R2 =
13.39 ± 0.71 46.49 ± 5.98 41.09 ± 3.78
58
R1 = H, R2 =
4.18 ± 0.19 9.62 ± 0.66 10.38 ± 0.59
59 R1, R2 = A(ACH2CH2A)2N(Pyridin-4-yl) 2.79 ± 0.13 5.45 ± 0.68 6.50 ± 0.77
60
R1, R2 =
4.22 ± 0.15 12.28 ± 0.72 11.14 ± 0.56
61
R1 = H, R2 =
1.21 ± 0.04 4.94 ± 0.28 3.56 ± 0.28
62 R1, R2 = A(ACH2CH2A)2NCH2CH2CH2N
(CH3)2
1.62 ± 0.06 4.21 ± 0.23 2.90 ± 0.07
63 R1, R2 = A(ACH2CH2A2N(Pyridin-4-yl) 5.25 ± 0.20 12.28 ± 0.37 7.71 ± 1.5
64 R1 = H, R2 = 1.66 ± 0.04 7.72 ± 0.45 5.58 ± 0.33
65
R1, R2 =
1.58 ± 0.04 4.25 ± 0.15 3.61 ± 0.23
66
R1 = H, R2 =
2.68 ± 0.12 10.19 ± 0.41 7.19 ± 0.31
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the lead compound, SSA (1) in HT29 cells, and by 2-fold in PC3 and
MDA-MB-231. Compounds 3 and 4 with a N,N-diethylamino group
at the ethylene or propylene acetamide groups were more active
than 2, but less potent than 1 in all three cell lines. Either an addi-
tional substituent at the acetamide nitrogen or removal of a sub-
stituent from the terminal nitrogen did not improve the activity
(5–14) dramatically. While maintaining the 4-methylsulfinylben-
zylidene at the C-1 position, we explored the SAR of selected basic
acyclic acetamide linkers (15–26). All these analogs led to reduced,
or a complete loss of potency. Selected basic acyclic acetamide
linkers with a 3,4,5-trimethoxybenzylidene group at the C-1
position (27–31) showed better activity than their corresponding
4-methylsulfinylbenzylidene analogs, but were less active than
corresponding 4-thiobenzylidene analogs. These compounds were
less active than 1, but still were highly active in vitro in all three
assays. We then expanded the SAR with selected basic acyclic acet-
amide linkers, while keeping the benzothiazol-2-ylmethylene
group as a fixed unit (32–35). These analogs demonstrated signif-
icant activity similar to their 4-methylthiobenzylidene counter-
parts. We also explored the anticancer activity of pyridin-4-
ylmethylene (36) and 4-sulfonylbenzylidene (37) analogs of 1.
These compounds were modestly active against all three cell lines,
but less potent than 1.
Screening results for basic cyclic amides 38–66 are summarized
in Table 2. Compounds 38–51, with a 4-methylthiobenzylidene
ring at the C-1 position and various basic cyclic acetamide linkers
at the C-3 position showed significant activity against cancer sim-
ilar to acyclic basic amide analogs 1–14. We also explored the SAR
of selected aryl modifications at the C-1 position compared to
selected basic cyclic acetamides (52–66). However, none of these
series, except the benzothiazolyl analogs (61–65), demonstrated
significant activity.
While maintaining the 4-methylthiobenzylidene at the C-1
position, we also examined the effects of basic aromatic acetamide
linkers at the C-3 position (Table 3). Compounds 67 and 68 with a
N,N-dimethylamino group at the phenyl group were inactive in all
three assays. Compounds with 2, 3, and 4-pyridylmethyl acetamide
(69, 70 and 71) showed inhibition but all with lesser potency than
lead 1.
We next explored the anticancer activity of neutral amides
(Table 4).
Compounds 72–78 have a 4-methylthiobenzylidene ring at the
C-1 position. Compound 72, with a benzyl group at the acetamide
linker, reduced the activity by 4-fold as compared to lead com-
pound in HT29 and PC3 cells and in MDA-MB-231 cells by 1.5-fold.
The aromatic heterocyclic compounds such as furan-2-yl analog 73
and thiophene-2-yl analog 74 had activity very similar to the cor-
responding phenyl analog 72 in all screening assays, but were less
active than lead 1. Compound 75, where the terminal dimethy-
lamino group of 1 was replaced by an isopropyl group, was not
active. The amino acid analogs 76–78 were >25-fold less potent
than the lead compound. By maintaining the 4-methylsulfinylben-
zylidene at the C-1 position, we explored the SAR of selected acet-
amide linkers. Among these three compounds (79–81), compound
79 with a benzyl group at the acetamide linker showed excellent
activity relative to lead 1. Furan-2-yl analog 80 also showed signif-
icant activity as compared to its methylthiobenzylidene analog 73,
but was less active than 1. Selected acetamide linkers with a 3,4,5-
Table 3
Screening data for basic aromatic amides 67–71.
Ar Cmpd R1 and R2 CC50 (mM)
HT29 PC3 MDA-MB-231
67 R1 = H, R2 = 4-(N,N-dimethylamino)benzyl >50.00 >50.00 >50.00
68 R1 = H, R2 = 4-(N,N-dimethylamino)phenyl >50.00 >50.00 30.60 ± 15.76
69 R1 = H, R2 = 4-pyridylmethyl 4.88 ± 0.18 5.83 ± 1.18 6.46 ± 0.93
70 R1 = H, R2 = 3-pyridylmethyl 4.83 ± 1.1 18.52 ± 7.78 7.36 ± 1.94
71 R1 = H, R2 = 2-pyridylmethyl 10.31 ± 0.79 13.64 ± 2.10 13.69 ± 1.85
Table 4
Screening data for neutral amides 72–86.
Ar Cmpd R1 and R2 CC50 (mM)
HT29 PC3 MDA-MB-231
72 R1 = H, R2 = benzyl 1.52 ± 0.39 16.36 ± 8.55 3.61 ± 1.87
73 R1 = H, R2 = furan-2-ylmethyl 2.08 ± 0.82 12.98 ± 6.83 3.40 ± 1.07
74 R1 = H, R2 = thiophen-2-ylmethyl 2.16 ± 0.71 11.03 ± 5.95 5.66 ± 2.69
75 R1 = H, R2 =ACH2CH2CH(CH3)2 >50.00 >50.00 >50.00
76 R1 = H, R2 = D-Alanine methyl ester 16.22 ± 2.61 44.18 ± 7.38 31.99 ± 2.33
77 R1 = H, R2 = L-Alanine methyl ester 23.92 ± 1.92 >50.00 38.86 ± 6.04
78 R1 = H, R2 = L-Histidine methyl ester 23.01 ± 3.09 >50.00 >50.00
79 R1 = H, R2 = benzyl 0.50 ± 0.23 2.64 ± 1.19 0.78 ± 0.32
80 R1 = H, R2 = furan-2-ylmethyl 1.00 ± 0.50 >50.00 2.73 ± 1.21
81 R1 = H, R2 =ACH2CH2CH(CH3)2 17.65 ± 1.11 20.23 ± 2.29 27.72 ± 3.37
82 R1 = H, R2 =ACH2CH2CH(CH3)2 5.24 ± 1.18 8.20 ± 1.92 8.73 ± 1.97
83 R1 = H, R2 = benzyl 23.56 ± 2.04 >50.00 19.63 ± 2.98
84 R1 = H, R2 = furan-2-ylmethyl 5.48 ± 1.70 26.44 ± 15.80 6.70 ± 2.23
85 R1 = H, R2 =ACH2CH2CH(CH3)2 >50.00 >50.00 24.20 ± 5.35
86 R1 = H, R2 = benzyl 2.14 ± 0.46 5.71 ± 1.75 3.68 ± 1.10
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trimethoxybenzylidene group, benzothiazol-2-ylmethylene group
or a pyridin-4-ylmethylene group at the C-1 position (82–86) did
not show improved activity.
Intestinal cells, cancer cells, and other cell types are known to
have specific amino acid (AA) uptake mechanisms that have been
utilized to increase drug uptake upon AA conjugation. For example,
conjugation of the active HSV agent acyclovir and penciclovir as
the valyl ester through the AA-COOH group results in blood levels
3–5 times that of the parent drug due to specific valine uptake
mechanisms.22,23 Inspired by this concept, compounds 87–89were
synthesized from N-methyl-N-(2-(methylamino)ethyl)acetamide
analogs 10, 22 and 31. All the three compounds, however, were
less active than their corresponding parent compounds (Table 5)
and potential gastric uptake remains untested.
We also explored a sulfonamide linkage due to its inherent
biostability and the opportunity to take advantage of further diver-
sity generation using commercially available sulfonyl chlorides as
well as the ease and typical high yields of sulfonamide formation.
Further, certain sulfonamides have been reported to demonstrate
anticancer activity.24–26 Hence, compounds 90–103 were synthe-
sized from 10 and 22 and screened in the three cancer cell panel.
A few analogs showed modest activity in these screens (Table 6).
A selected set of analogs were additionally screened against a
panel of six cancer cell lines at St. Jude Children’s Research Hospital
consisting of four acute lymphoblastic leukemia (ALL) cell lines,
one lymphoma line and a cell line derived from a mouse model
of choroid plexus carcinoma (CPC), as described in Appendix A,
supplementary materials. The selected compounds included the
most potent series, namely, compounds 1–14, 32–35, 38–51, 59,
61–65 and 79. Out of the analog series presented in Tables 4 and
5, representative analogs 72–74, 79, 82, 84, 87 and 89 were also
evaluated against this panel. Table 7 lists screening results for lead
1 and the analogs that show activity against at least one of these
cancer cells. Compounds 5, 33, 35, 50, 62 and 89 stand out as
nanomolar growth inhibitors of at least one type of acute lym-
phoblastic leukemia cancer cell line on this screening panel. Fur-
ther, compound 79 shows low micromolar growth inhibition
against all lymphoblastic leukemia cell lines on the screening panel
while very weak activity against the choroid plexus carcinoma cell
line. These analogs with the exception of 89 are also good inhibi-
tors of the HT29, PC3 and MDA cancer cell lines. Interestingly, a
related scaffold containing a 3,4,5-trimethoxyphenyl aryl moiety,
the indomethacin analog of compound 27 was previously shown
to inhibit potently proliferation of multiple cancer cell lines
through interfering with tubulin polymerization.27 Thus, we iden-
tified a number of analogs potently inhibiting multiple types of
cancer cell lines. These compounds may be pursued in future work
as potential anticancer leads. Of note, the parent hit sulindac sul-
fide amide (SSA, 1) showed no activity against cancer cell lines in
this panel (Table 7).
Cytotoxicity considerations and computed physicochemical
properties
Lipophilicity (in addition to molecular weight and other molec-
ular characteristics) is a crucial physicochemical property to con-
sider during lead optimization.28–30 Like the parent compound,
SSA, most analogs presented contain a positively charged amine,
which coupled with high lipophilicity raises concern that such
compounds may accumulate in cell membranes interacting with
non-polar lipid chains while the positively charged amine associ-
ates with negatively charged head groups of fatty acids. This may
lead to cytotoxicity through membrane destabilization. Selected
series and representative analogs have been counter-screened for
cytotoxicity against BJ cells, a normal human foreskin fibroblast
cell line31 where cytotoxicity was determined at 10 mM drug con-
centration. The following compounds were evaluated for cytotoxi-
city in this assay: compounds 1–14, 32–35, 38–51, 59, 61–66, 72–
74, 79, 82, 84, 87 and 89 (Table 7). All compounds screened showed
EC50 >7.57 mM in the BJ cytotoxicity assay suggesting that these
compounds are not overtly toxic to this ‘‘normal” fibroblast cell
line (Table 7). Compound 79 lacks a charged amine, yet it has the
highest efficacy against all three cancer cell lines among the pre-
sented analogs while also potently inhibiting five lymphoblastic
leukemia cell lines. Replacement of the thiomethyl (SSA) with
the polar methylsulfinyl in 79 decreases lipophilicity of this analog.
A study examining correlations between physicochemical prop-
erties and toxicological outcomes has shown that topological polar
surface area (TPSA) and cLogP properties correlate with in vivo
toxicity in a set of 245 preclinical Pfizer compounds for which ani-
mal toxicity and exposure data has been collected.32 The ‘least tox-
ic’ group was reported to have TPSA >75 Å2 and cLogP <3. We
computed physicochemical properties relevant to lipophilicity for
selected representative analogs in the most potent series, including
LogP, LogD, TPSA and lipophilic efficiency (LipE), as shown in
Table A.1, Appendix A. While listed compounds have LogP >3
and show only modest variations compared to lead 1 (LogP
5.03), TPSA values are higher for most analogs relative to SSA
which may be considered an improvement compared to the parent
compound. Analogs 32–34, 61 and 80 have the highest (close to
75 Å2) TPSA values compared to lead 1 (TPSA 57.64 Å2). Com-
pounds 40, 41, 44, 61, 62 have LogD values less than 3, compared
to 4.41 of lead 1.
Lipophilic efficiency (LipE) relates potency to lipophilicity and
may be used to assess and optimize binding efficiency in the con-
text of lipophilicity. LipE listed in Table A.1 (Appendix A) was cal-
culated as LipE = pCC50 (HT29) – logD (at pH 7.4). While the
optimal target range for LipE is considered between 5 and 7, these
analogs show a trend of slight improvement compared to SSA (LipE
1.78), compounds 41, 61 and 62 possessing LipE >3. It is important
to note that the CC50 values utilized for computing LipE results for
these compounds were determined using whole cell screening
assays. Generally, we would expect more potent in vitro dose-
response activities against a specific protein target compared to
Table 5
Screening data for compounds 87–89.
Cmpd CC50 (mM)
HT29 PC3 MDA-MB-231
87 3.72 ± 1.50 7.08 ± 0.77 7.33 ± 0.85
88 30.20 ± 0.59 >50.00 >50.00
89 10.73 ± 0.71 17.65 ± 1.89 18.84 ± 1.61
Table 6
Screening data for compounds 90–103.
Cmpd CC50 (mM)
HT29 PC3 MDA-MB-231
90 4.04 ± 0.52 15.54 ± 1.39 11.57 ± 1.22
91 4.20 ± 0.43 14.34 ± 1.97 10.09 ± 1.00
92 8.82 ± 1.16 >50.00 >50.00
93 12.92 ± 1.24 >50.00 >50.00
94 16.20 ± 3.80 >50.00 >50.00
95 35.28 ± 7.75 >50.00 >50.00
96 >50.00 >50.00 >50.00
97 12.36 ± 0.98 42.59 ± 7.47 12.54 ± 0.80
98 42.64 ± 3.16 >50.00 >50.00
99 6.09 ± 0.30 8.20 ± 0.57 12.17 ± 1.37
100 6.18 ± 0.39 10.95 ± 0.96 17.77 ± 2.46
101 3.99 ± 0.49 8.96 ± 1.79 29.08 ± 7.05
102 6.35 ± 1.06 7.52 ± 1.16 32.08 ± 8.17
103 10.60 ± 1.91 9.20 ± 1.46 >50.00
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whole cell activities which then would reflect in calculated LipE
values. Thus, it is not surprising that LipE values obtained for these
compounds are lower than the accepted optimal norms assessed in
enzymatic, target-based assays.
A number of analogs in the reported series were designed to
improve metabolic stability, based on metabolic site liability pre-
dictions using the CYP3A4 metabolism model implemented in
the StarDrop software. For example, introducing a benzothiazolyl
group as in 32, 61 is predicted to remove metabolically labile sites
associated with the 4-methylthiophenyl group in SSA (as shown in
Figs. A.2, A.4, compared to SSA in Fig. A.1, Appendix A). In addition,
metabolic vulnerability may be also reduced by cyclization of the
amine as exemplified for compounds 40 and 61 (Figs. A.3 and A.4
in Appendix A, respectively).
In summary, we report herein an extensive SAR study of sulin-
dac amide analogs that show significant anticancer activity in
HT29, PC3 and MDA-MB-231 proliferation assays. Our primary
goal in this work was to expand diversity around positions of the
basic indene structure for probing anticancer activities of diverse
amide analogs of sulindac sulfide amide (SSA). The most potent
compound identified, compound 79, shows significant activity
and potency compared to the lead compound SSA (1). This analog
also has potent growth inhibitory activity against the five lym-
phoblastic leukemia cell lines screened, against which SSA is inac-
tive. Compound 79with a benzyl group at the acetamide linker and
a 4-methylsulfinylbenzylidene group at the C-1 position is a
neutral analog lacking the basic amine moiety of SSA. Introducing
various heterocycles or substituents in place of the 4-methylth-
iobenzylidine and the dimethylethylamine in lead compound 1
resulted in analog series that maintain growth inhibition at low
micromolar potency in all three cancer cell lines suggesting that
there is fair tolerance for alterations in these regions while main-
taining good anticancer activity. Screening against the panel of
six additional cancer cell lines identified five new analogs, com-
pounds 5, 33, 35, 50, 62, that also show highly potent growth inhi-
bitory activity against acute lymphoblastic leukemia cell line(s) in
which the parent compound 1was inactive. While possessing com-
parable anticancer activity to lead 1, a number of analogs within
the presented series show improved computed physicochemical
properties compared to compound 1, namely, improvement of
lipophilic efficiency (LipE) and/or topological polar surface area
(TPSA) and/or LogD properties. Among potent analogs that show
improvement of physicochemical properties are compounds 32–
34 with a benzothiazol-2-ylmethylene at the C-1 position and
acyclic basic amide linkers, the series 40, 41, 44 containing various
basic cyclic amide groups, analogs 61, 62 combining benzothiazol-
2-ylmethylene at the C-1 position with basic cyclic amides at C-3,
while compounds 79, 80 containing a benzyl and furanylmethyl
amide group are neutral analogs. Analogs screened in a BJ cell cyto-
toxicity assay showed no toxicity against this fibroblast cell line.
Our original design parameters were based on generation of struc-
tural diversity and ease of synthesis while, for the most part, main-
taining a basic group near the carboxamide generated during
coupling. Our presumption, based on earlier modeling and testing
of our lead agent SSA, has been that the basic amine moiety replac-
ing carboxylate in sulindac would attenuate or abrogate COX bind-
ing due to charge-charge interactions of the protonated amine with
positively charged amino acid side chains in the COX 1–2 active
sites.13,18 Whether compound 79, a neutral analog of sulindac lack-
ing a basic amine, has any COX activity is presently unknown. This
hypothesis and the mechanism of action for the new compounds
presented herein will require experimental confirmation, and such
experiments will be the focus of future work. Selected active com-
pounds may also serve as potential candidates for formulation and
in vivo assessment for bioavailability and efficacy.
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